Puneet Tyagi
Puneet Tyagi
AstraZeneca
Verified email at medimmune.com
Title
Cited by
Cited by
Year
Hybrid dendrimer hydrogel/PLGA nanoparticle platform sustains drug delivery for one week and antiglaucoma effects for four days following one-time topical administration
H Yang, P Tyagi, RS Kadam, CA Holden, UB Kompella
ACS nano 6 (9), 7595-7606, 2012
1502012
Polyamidoamine dendrimer hydrogel for enhanced delivery of antiglaucoma drugs
CA Holden, P Tyagi, A Thakur, R Kadam, G Jadhav, UB Kompella, ...
Nanomedicine: nanotechnology, biology and medicine 8 (5), 776-783, 2012
1202012
Acidic nanoparticles are trafficked to lysosomes and restore an acidic lysosomal pH and degradative function to compromised ARPE-19 cells
GC Baltazar, S Guha, W Lu, J Lim, K Boesze-Battaglia, AM Laties, P Tyagi, ...
PloS one 7 (12), e49635, 2012
1002012
Light-activated, in situ forming gel for sustained suprachoroidal delivery of bevacizumab
P Tyagi, M Barros, JW Stansbury, UB Kompella
Molecular pharmaceutics 10 (8), 2858-2867, 2013
732013
Targeted Intraceptor Nanoparticle Therapy reduces Angiogenesis and Fibrosis in Primate & Murine Macular Degeneration.
L Luo, X Zhang, Y Hirano, P Tyagi, P Barabás, H Uehara, TR Miya, ...
ACS nano, 2013
692013
Intravitreal poly (L-lactide) microparticles sustain retinal and choroidal delivery of TG-0054, a hydrophilic drug intended for neovascular diseases
NB Shelke, R Kadam, P Tyagi, VR Rao, UB Kompella
Drug delivery and translational research 1 (1), 76-90, 2011
572011
RETRACTED: Influence of choroidal neovascularization and biodegradable polymeric particle size on transscleral sustained delivery of triamcinolone acetonide
RS Kadam, P Tyagi, HF Edelhauser, UB Kompella
International journal of pharmaceutics 434 (1-2), 140-147, 2012
492012
Anti-inflammatory and antiangiogenic effects of nanoparticle-mediated delivery of a natural angiogenic inhibitor
J Jin, KK Zhou, K Park, Y Hu, X Xu, Z Zheng, P Tyagi, UB Kompella, J Ma
Investigative ophthalmology & visual science 52 (9), 6230-6237, 2011
482011
Supercritical fluid technology based large porous celecoxib–PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks …
DS Dhanda, P Tyagi, SS Mirvish, UB Kompella
Journal of Controlled Release 168 (3), 239-250, 2013
452013
Comparison of suprachoroidal drug delivery with subconjunctival and intravitreal routes using noninvasive fluorophotometry
P Tyagi, RS Kadam, UB Kompella
PloS one 7 (10), e48188, 2012
452012
Oral peptide delivery: Translational challenges due to physiological effects
P Tyagi, S Pechenov, JA Subramony
Journal of Controlled Release 287, 167-176, 2018
442018
Suprachoroidal delivery in a rabbit ex vivo eye model: influence of drug properties, regional differences in delivery, and comparison with intravitreal and intracameral routes
RS Kadam, J Williams, P Tyagi, HF Edelhauser, UB Kompella
Molecular vision 19, 1198, 2013
402013
Nanotherapeutics in oral and parenteral drug delivery: Key learnings and future outlooks as we think small
P Tyagi, JA Subramony
Journal of Controlled Release 272, 159-168, 2018
392018
Flt23k nanoparticles offer additive benefit in graft survival and anti-angiogenic effects when combined with triamcinolone
YK Cho, H Uehara, JR Young, P Tyagi, UB Kompella, X Zhang, L Luo, ...
Investigative ophthalmology & visual science 53 (4), 2328-2336, 2012
382012
Silibinin, dexamethasone, and doxycycline as potential therapeutic agents for treating vesicant-inflicted ocular injuries
N Tewari-Singh, AK Jain, S Inturi, DA Ammar, C Agarwal, P Tyagi, ...
Toxicology and applied pharmacology 264 (1), 23-31, 2012
332012
Macromolecule nanotherapeutics: approaches and challenges
P Tyagi, JL Santos
Drug discovery today 23 (5), 1053-1061, 2018
222018
Nanoparticle-mediated expression of a Wnt pathway inhibitor ameliorates ocular neovascularization
Z Wang, R Cheng, K Lee, P Tyagi, L Ding, UB Kompella, J Chen, X Xu, ...
Arteriosclerosis, thrombosis, and vascular biology 35 (4), 855-864, 2015
212015
Dendrimer hydrogels
H Yang, PN Desai, CA Holden, UB Kompella, P Tyagi
US Patent App. 13/022,974, 2011
212011
Development and evaluation of a gastroretentive drug delivery system for the low-absorption-window drug celecoxib
J Ali, P Tyagi, A Ahuja, S Baboota, S Hasan
PDA journal of pharmaceutical science and technology 61 (2), 88-96, 2007
112007
Silica microparticles for sustained zero-order release of an anti-CD40L antibody
P Tyagi, M Koskinen, J Mikkola, L Leino, A Schwarz
Drug Delivery and Translational Research, 2017
42017
The system can't perform the operation now. Try again later.
Articles 1–20